Dr. Reddy's introduces generic Emend
Dr. Reddy’s is launching a generic of Emend (fosaprepitant for injection). The drug had previously been approved by the Food and Drug Administration.
“We are pleased to be among the first generics to launch this product,” said Marc Kikuchi, Dr. Reddy’s CEO, North America generics. “This is a great addition to our injectable portfolio in the U.S. market as we continue to augment our product offering and drive growth for the hospital segment.”
The Emend for injection brand had a market value of $279 million for the most recent 12 months ending in July 2019, according to IQVIA.
Dr. Reddy’s product is available in a 150-mg single-dose vial for reconstitution.
“We are pleased to be among the first generics to launch this product,” said Marc Kikuchi, Dr. Reddy’s CEO, North America generics. “This is a great addition to our injectable portfolio in the U.S. market as we continue to augment our product offering and drive growth for the hospital segment.”
The Emend for injection brand had a market value of $279 million for the most recent 12 months ending in July 2019, according to IQVIA.
Dr. Reddy’s product is available in a 150-mg single-dose vial for reconstitution.